Publications by authors named "Jean-Michel Hannoun Levi"
Background: Nodes are the second site for prostate cancer recurrence. Whole-pelvic radiotherapy (WPRT) has shown superiority over nodal stereotactic body radiotherapy (SBRT) in two retrospective cohorts. We aimed to compare both modalities and assess factors associated with treatment outcomes.
View Article and Find Full Text PDFApproximately 10 to 15% of patients with breast cancer will have a local recurrence after initial conservative treatment or mastectomy. Total mastectomy has historically been the standard treatment for local recurrence. However, the question of reirradiation may arise as part of a second conservative treatment in conjunction with segmentectomy or in the case of chest wall recurrence to improve local control.
View Article and Find Full Text PDFArticle Synopsis
- This review investigates how artificial intelligence (AI) can improve interventional radiotherapy (IRT) by making workflows more efficient and enhancing patient care.
- Analyzing 78 studies from 2002 to 2024, it highlights advancements in areas like treatment planning, contouring, outcome prediction, and quality assurance.
- While AI shows potential for reducing procedure times and personalizing treatments, challenges like clinical validation and quality assurance remain important to address.
Objective: To report the results of a multicenter cohort of preoperative brachytherapy (PBT) for treatment of early-stage cervical cancer (ESCC).
Methods: A retrospective analysis was conducted among five French comprehensive cancer centers on behalf of the SFRO Brachytherapy Group to examine the outcome of patients with ESCC who received PBT between 2001 and 2019 because of adverse prognostic factors (tumor size >2 cm, presence of lymphovascular invasion, adenocarcinoma).Brachytherapy was followed 4-8 weeks later by surgery.
Background: The onset of castration-resistance is associated with dismal outcomes in patients with prostate cancer (PCa). Metastasis directed therapy has been investigated in multiple disease settings and may improve outcomes in selected patients. Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC).
View Article and Find Full Text PDFPurpose: Breast brachytherapy (BB) represents an important radiation therapy modality in modern breast cancer treatments. Currently, BB is mainly used for accelerated partial breast irradiation (APBI), local boost after whole breast radiation therapy (WBRT), and as salvage re-irradiation after second lumpectomy (APBrl). Two multi-catheter interstitial brachytherapy (MIB) techniques can be offered: intra-operative (IOB) and post-operative (POB) brachytherapy.
View Article and Find Full Text PDFPurpose: To analyze late toxicity after very accelerated partial breast irradiation (VAPBI) for low-risk breast cancer.
Materials: Methods: In this retrospective, observational, international multicenter study (HDH F20220713143949), patients with low-risk breast cancer underwent lumpectomy + vAPBI (high-dose rate multicatheter interstitial brachytherapy-MIBT). VAPBI was performed with 4(4x6.
Purpose: For second ipsilateral breast tumor event (2ndIBTE), conservative treatment (CT) involving wide local excision plus accelerated partial breast reirradiation (APBrI) is increasingly used as an alternative to mastectomy. This study investigates the impact of APBrI technique and multicatheter interstitial high dose-rate brachytherapy (MIB) dosimetry parameters on toxicity and survival in patients with 2ndIBTE.
Materials-methods: Data from patients with 2ndIBTE treated with CT, were analyzed.
Purpose: For second ipsilateral breast tumor event (2nd IBTE), second conservative treatment (2nd CT) combining lumpectomy plus accelerated partial breast reirradiation (APBrI) represents a curative option. The aim of this study was to analyze oncological prognostic factors for patients with a 2nd IBTE treated with 2nd CT.
Methods And Materials: An analysis of clinical practices was conducted across 7 academic hospitals/cancer centers in 6 European countries based on the GEC-ESTRO database.
Article Synopsis
- This study explores the effectiveness of Stereotactic Ablative Radiotherapy (SABR) as a non-invasive treatment for early-stage metachronous lung cancer (MLC) compared to primary lung cancer (PLC).
- A total of 137 patients were reviewed, with similar outcomes in overall survival, progression-free survival, and local control for both MLC and PLC groups after receiving SABR.
- The findings suggest that SABR is a safe and viable treatment option for patients with localized MLC, achieving comparable results to those with PLC over a median follow-up period of 53 months.
Purpose: For low-risk breast cancer, accelerated partial breast irradiation (APBI) is a level 1 evidence procedure. Brachytherapy based very APBI (vAPBI) makes it possible to perform adjuvant irradiation in 4 to 1 fraction. However, vAPBI organization is critical.
View Article and Find Full Text PDFArticle Synopsis
- - A 2021 survey of French radiation oncology residents found that 80% feel their brachytherapy training is inadequate, even though interest in the field remains high at 86% participation.
- - While proficiency in certain brachytherapy techniques has slightly improved since 2012, significant gaps remain, especially in prostate brachytherapy, with many residents reporting minimal hands-on experience.
- - Major barriers to effective training include the necessity of visiting multiple centers for different treatments, insufficient brachytherapy activities at their home institutions, and competing hospital responsibilities, highlighting the need for improved structured training programs.
Article Synopsis
- Radiotherapy dose escalation, specifically through the addition of high dose-rate brachytherapy (HDR-BB), has been shown to enhance biochemical control in patients with intermediate- to high-risk prostate cancer, as validated by this study involving 709 patients.* -
- After a median follow-up of 62 months, the results revealed a 5-year biochemical control rate of 87.5%, with 91% for intermediate-risk and 85% for high-risk categories, alongside high rates of clinical relapse-free survival and overall survival.* -
- The study concluded that HDR-BB is effective and well-tolerated when used with external beam radiotherapy, and suggests that integrating new hormonal treatments or refined fractionation regimens could
Purpose: To analyze long-term oncological outcome after 2nd conservative treatment (2CT) for patients with ipsilateral 2nd ipsilateral breast tumor event (2IBTE).
Materials/methods: In this retrospective observational study (N°F20210402152843), patients with 2IBTE underwent 2CT (lumpectomy + tumor bed re-irradiation). 3IBTE (3IBTE-FS), regional relapse- (RRFS) and metastatic disease- (MD-FS) free survivals as well as disease-free (DFS), specific (SS) and overall (OS) survival were analyzed.
Purpose: In recent years, results with mature follow-up have been reported for several Phase III trials randomizing women to receive whole breast irradiation (WBI) versus varying modalities of partial breast irradiation (PBI). It is important to recognize that these methods vary in terms of volume of breast tissue treated, dose per fraction, and duration of therapy. As such, clinical and technical guidelines may vary among the various PBI techniques.
View Article and Find Full Text PDFPurpose: To report the results of the (SiFEPI) phase 2 prospective trial.
Materials/methods: The SiFEPI trial (NCT02104362) evaluated a single fraction of high-dose rate brachytherapy (HDB) for low- (LR) and favorable-intermediate (FIR) risk prostate cancers. After rectal spacer placement, a single fraction of 20 Gy was delivered to the prostate.
Purpose: To analyze the oncological outcome in elderly (>70 years) prostate cancer after high-dose rate brachytherapy (HDB) boost.
Materials/methods: In this retrospective study, patients with intermediate (IR) and high-risk (HR) prostate cancer underwent external beam radiation therapy (EBRT) followed by HDB boost with/without androgen deprivation therapy (ADT). The impact of age (≤70y vs.
Purpose: To analyze the literature that addresses radiation therapy for intermediate and high-risk prostate cancer (PC) in the elderly.
Patients And Methods: A PubMed literature search was conducted including articles from 01/01/2000 to 30/06/21, with the following keywords: PC, radiotherapy/brachytherapy and elderly. The analysis mainly focused on the issue of under-treatment in the elderly and the benefit/risk balance of irradiation.
Introduction: Radical proctectomy (RP-TME) with neo adjuvant chemoradiotherapy (nCRT) remains the standard treatment for T2-T3 rectal cancer. Organ preservation (OP) using CRT and a "watch and wait" strategy (W&W) is a field of research. Planned organ preservation can be proposed for early T1-T3 using contact X-ray brachytherapy (CXB).
View Article and Find Full Text PDFObjective: To report long-term oncological and toxicity outcomes after high-dose-rate brachytherapy (HDB) followed by oncologic surgery for patients with early-stage cervical cancer.
Methods And Materials: From 2005 to 2019, all patients treated with preoperative HDB at Antoine Lacassagne Cancer Center for early-stage (IB1-IB2-IIA - FIGO 2018) cervical cancer with local relapse risk factors were included. HDB was performed followed by hysterectomy.
Purpose: Brachytherapy (BT) boost after radio-chemotherapy (RCT) is a standard of care in the management of locally advanced cervical cancer (LACC). As there is no consensus on high-dose-rate (HDR) BT fractionation schemes, our aim was to report the oncological outcome and toxicity profile of four different schemes using twice-a-day (BID) HDR-BT.
Patients And Methods: This was an observational, retrospective, single institution study for patients with LACC receiving a HDR-BT boost.